[HTML][HTML] The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
G Greenfield, S McPherson, K Mills… - Journal of translational …, 2018 - Springer
The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential
thrombocythemia (ET) and primary myelofibrosis (PMF) are linked by a propensity to …
thrombocythemia (ET) and primary myelofibrosis (PMF) are linked by a propensity to …
[PDF][PDF] Myelofibrosis: clinicopathologic features, prognosis, and management
JM O'Sullivan, CN Harrison - Clin Adv Hematol Oncol, 2018 - hematologyandoncology.net
Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
[HTML][HTML] Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
A Tefferi, M Mudireddy, F Mannelli, KH Begna… - Leukemia, 2018 - nature.com
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were
retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was …
retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was …
The mutational landscape of accelerated-and blast-phase myeloproliferative neoplasms impacts patient outcomes
CJ McNamara, T Panzarella, JA Kennedy… - Blood …, 2018 - ashpublications.org
There is a paucity of data regarding the impact of mutations on outcomes in accelerated-
phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is …
phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is …
[HTML][HTML] JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
AS McKenney, AN Lau… - The Journal of …, 2018 - Am Soc Clin Investig
Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow
failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the …
failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the …
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
Myeloproliferative neoplasms (MPNs) are a group of blood cancers that arise following the
sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells …
sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells …
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
G Venton, F Courtier, A Charbonnier… - American journal of …, 2018 - Wiley Online Library
Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have
variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of …
variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of …
[HTML][HTML] JARID2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells
How specific genetic lesions contribute to transformation of non-malignant myeloproliferative
neoplasms (MPNs) and myelodysplastic syndromes (MDSs) to secondary acute myeloid …
neoplasms (MPNs) and myelodysplastic syndromes (MDSs) to secondary acute myeloid …
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
RK Rampal, JO Mascarenhas, HE Kosiorek… - Blood …, 2018 - ashpublications.org
Myeloproliferative neoplasms (MPN), including polycythemia vera, essential
thrombocythemia, and primary myelofibrosis, have a propensity to evolve into accelerated …
thrombocythemia, and primary myelofibrosis, have a propensity to evolve into accelerated …
How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms
O Odenike - Blood, The Journal of the American Society of …, 2018 - ashpublications.org
The classic Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms (MPNs)
are a heterogeneous group of hematopoietic stem-cell diseases, characterized by activated …
are a heterogeneous group of hematopoietic stem-cell diseases, characterized by activated …